Thermo Fisher unveils new assays; St. Jude launches CRT-D device in Japan;

@FierceMedDev: Despite retiring in 2011, ex-Medtronic CEO Bill Hawkins made about $8M from the company in FY12. Item | Follow @FierceMedDev

 @MarkHFierce: Biomet has cut back its year-over-year losses due to sales growth in its major divisions. Story | Follow @MarkHFierce

 @DamianFierce: J&J's device sales stayed mostly flat as the company's overall earnings dropped. More | Follow @DamianFierce

> Fresh off its $925 million acquisition of One Lambda, Thermo Fisher ($TMO) got a CE mark for its Tacrolimus immunoassay and announced a new generation of its Indiko analyzer, designed to test for drug abuse. News

> St. Jude Medical ($STJ) is launching in Japan the Unify Quadra CRT-D, engineered to treat heart failure by resynchronizing the heart beat. Release

> Becton Dickinson's ($BDX) diagnostics unit got 510(k) clearance for new blood culture bottles, designed for use in sepsis and infection diagnostics. More

> ICU Medical ($ICUI) reported a 3.6% drop in second-quarter earnings but still expects to pull in revenues between $318 million and $325 million for the year. Report

> TriReme Medical got 510(k) clearance for more sizes of Glider PTCA, the world's only torqueable balloon catheter, treating complex percutaneous coronary interventions. Article

> The litigation between Sequenom ($SQNM) and Aria Diagnostics continues, as Sequenom has filed an appeal of a court's ruling that Aria could continue to sell its Down syndrome-related diagnostic while the companies await trial. Item

Biotech News

 @FierceBiotech: DeCode, Genentech find gene mutation marks protection against ‪Alzheimer's‬. More | Follow @FierceBiotech

 @JohnCFierce: Elan is priced for a buyout deal? Oh, my. Who would buy that company just now? Report | Follow @JohnCFierce

 @RyanMFierce: Alnylam up 45% after ALN-TTR02 passes Phase I. Could this be the RNAi drug we've all been waiting for? | Follow @RyanMFierce

> Investors on high alert as D-Day arrives for Vivus's Qnexa. Article

> AZ's MedImmune axing 200 in California R&D restructuring. News

> Analysts' frenzy over PhI success helps ignite Alnylam shares. Story

Pharma News

 @FiercePharma: Simponi‬ for colitis, J&J says: Janssen unit asks FDA to OK new use for Remicade follow-up drug. More | Follow @FiercePharma

> J&J drug sales hold their own, thanks to foreign growth. Report

> AZ puts Brilinta up for another head-to-head fight with Plavix. Article

> Appeals court ruling threatens pay-to-delay deals. News

> Par could fetch up to $2.5B from rival genericsmaker. More

Pharma Manufacturing News

> Lonza seeks growth in China after securing IP. Story

> Feds get conviction in fake J&J test strips case. More

> India regulator orders Aurobindo, others to close 12 plants. Report

> Hospira blames supplier's bad vials for latest recall. Article

Biotech Research News

> Researchers use gene therapy to treat spinal muscular atrophy. Article

> New 'molecular grenade' used to attack tumor cells. Report

> Researcher rebuts rival finding that ovarian stem cells exist. Story

> Rare gene mutation protects against Alzheimer's. More

> Alnylam generates preclinical buzz with RNAi hemophilia drug. News

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.